New sedative aims to calm ICU patients safely
NCT ID NCT06222294
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested a sedative called remimazolam tosilate in 214 ICU patients who were on breathing machines. The goal was to see if it works as well as or better than the standard sedative propofol. Patients received either remimazolam or propofol, and researchers measured how often they stayed at the right sedation level without needing extra medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remimazolam tosilate
- What this could lead to
- If successful, this could offer a safer sedation option for ICU patients on breathing machines.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. Remimazolam may not be more effective or safer than current sedatives like propofol.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEDATION IN THE ICU are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.